Celltrion's biosimilar of J&J's Remicade reviewed favorably by FDA staffers

FDA staff reviewers were supportive of the Remicade biosimilar from Celltrion ahead of next week's advisory committee meeting. The reviewers said that the drug is "highly similar" to the branded product in terms of safety, purity and potency. The drug from the South Korean company is already available in Europe and the U.K., where it has been selling well as wholesalers for the product have been discounting it deeply in a pricing battle with Pfizer's ($PFE) Hospira, which is also selling a version of the drug. Merck ($MRK), which sells Remicade outside of the U.S., recently said it would cut the price in the U.K. by 25% to better compete with biosimilars there. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.